Spots Global Cancer Trial Database for lymphoblastic
Every month we try and update this database with for lymphoblastic cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Nilotinib With Chemotherapy for the Treatment of Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia | NCT00905398 | Precursor B-Cel... Acute Lymphobla... | Nilotinib | 18 Years - 75 Years | Universidade Federal do Rio de Janeiro | |
| AC220 for Children With Relapsed/Refractory ALL or AML | NCT01411267 | Lymphoblastic L... Myelogenous Leu... | AC220 Cytarabine Etoposide Methotrexate | 1 Month - 21 Years | Therapeutic Advances in Childhood Leukemia Consortium | |
| Therapy for Pediatric Relapsed or Refractory Acute Lymphoblastic Leukemia | NCT00186875 | Acute Lymphobla... Lymphoma, Lymph... | Etoposide, cyta... methotrexate, t... mitoxantrone, c... L-asparaginase,... chemotherapy, i... Hematopoietic S... Natural Killer ... | - 21 Years | St. Jude Children's Research Hospital | |
| Safety and Efficacy of an Adult Acute Lymphoblastic Leukemia Chemotherapy for Adult Lymphoblastic Lymphoma | NCT00195871 | Lymphoblastic L... | Prednisone, vin... hematopoietic s... | 18 Years - 59 Years | Centre Henri Becquerel | |
| Safety and Efficacy of Marqibo in Relapsed Acute Lymphoblastic Leukemia | NCT00495079 | Acute Lymphobla... | Marqibo® (vincr... | 18 Years - | Spectrum Pharmaceuticals, Inc | |
| Safety and Efficacy of Marqibo in Relapsed Acute Lymphoblastic Leukemia | NCT00495079 | Acute Lymphobla... | Marqibo® (vincr... | 18 Years - | Spectrum Pharmaceuticals, Inc | |
| Erwinase for Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) (IND 104224) | NCT00928200 | Relapsed Acute ... Allergy to PEG ... Allergy to Nati... | Erwinase Vincristine Dexamethasone Doxorubicin Cytarabine Methotrexate Triple Intrathe... Dexrazoxane | 1 Year - 21 Years | Therapeutic Advances in Childhood Leukemia Consortium | |
| EZN-3042 Administered With Re-induction Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL) | NCT01186328 | Lymphoblastic L... Lymphoblastic L... Leukemia, Lymph... Leukemia, Lymph... | EZN-3042 Cytarabine Doxorubicin Prednisone Vincristine PEG-asparaginas... Methotrexate Hydrocortisone | 1 Year - 21 Years | Therapeutic Advances in Childhood Leukemia Consortium | |
| Alemtuzumab and Clofarabine for Relapsed or Refractory Acute Lymphoblastic Leukemia | NCT00983528 | Acute Lymphobla... | Alemtuzumab Clofarabine | 16 Years - | University of California, San Diego | |
| A Study Of Panobinostat In Children With Refractory Hematologic Malignancies | NCT01321346 | Lymphoblastic L... Myelogenous Leu... Hodgkin's Disea... Non-Hodgkin's L... | Panobinostat Cytarabine Panobinostat | 8 Years - 21 Years | Therapeutic Advances in Childhood Leukemia Consortium | |
| A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL | NCT01483690 | Acute Lymphobla... Precursor B-Cel... Precursor T-Cel... | Decitabine Vorinostat Vincristine Dexamethasone Mitoxantrone Pegaspargase Methotrexate | 1 Year - 21 Years | Therapeutic Advances in Childhood Leukemia Consortium | |
| Nilotinib With Chemotherapy for the Treatment of Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia | NCT00905398 | Precursor B-Cel... Acute Lymphobla... | Nilotinib | 18 Years - 75 Years | Universidade Federal do Rio de Janeiro | |
| Study Protocol: Study on Incidence and Risk Factors of Mold Infections in Children During Leukemia Treatment | NCT05774990 | Leukemia, Myelo... Acute Lymphobla... | - 17 Years | University of Southern Denmark | ||
| Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL | NCT00981799 | Relapsed T-Cell... Relapsed T-Cell... | Nelarabine Etoposide Cyclophosphamid... Methotrexate Filgrastim | 1 Year - 21 Years | Therapeutic Advances in Childhood Leukemia Consortium | |
| A Trial of Temsirolimus With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma | NCT01614197 | Lymphoblastic L... Lymphoblastic L... Peripheral T-ce... | Temsirolimus Etoposide Cyclophosphamid... Methotrexate Hydrocortisone Cytarabine | 1 Year - 21 Years | Therapeutic Advances in Childhood Leukemia Consortium | |
| Comparing Two Diets in Patients Undergoing HSCT or Remission Induction Chemo for Acute Leukemia and MDS (UF-BMT-LDND-101) | NCT03016130 | Leukemia Myelodysplastic... | Diet | 18 Years - | University of Florida | |
| A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL | NCT01483690 | Acute Lymphobla... Precursor B-Cel... Precursor T-Cel... | Decitabine Vorinostat Vincristine Dexamethasone Mitoxantrone Pegaspargase Methotrexate | 1 Year - 21 Years | Therapeutic Advances in Childhood Leukemia Consortium | |
| AC220 for Children With Relapsed/Refractory ALL or AML | NCT01411267 | Lymphoblastic L... Myelogenous Leu... | AC220 Cytarabine Etoposide Methotrexate | 1 Month - 21 Years | Therapeutic Advances in Childhood Leukemia Consortium | |
| Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL | NCT00981799 | Relapsed T-Cell... Relapsed T-Cell... | Nelarabine Etoposide Cyclophosphamid... Methotrexate Filgrastim | 1 Year - 21 Years | Therapeutic Advances in Childhood Leukemia Consortium | |
| Therapy for Pediatric Relapsed or Refractory Acute Lymphoblastic Leukemia | NCT00186875 | Acute Lymphobla... Lymphoma, Lymph... | Etoposide, cyta... methotrexate, t... mitoxantrone, c... L-asparaginase,... chemotherapy, i... Hematopoietic S... Natural Killer ... | - 21 Years | St. Jude Children's Research Hospital | |
| Alemtuzumab and Clofarabine for Relapsed or Refractory Acute Lymphoblastic Leukemia | NCT00983528 | Acute Lymphobla... | Alemtuzumab Clofarabine | 16 Years - | University of California, San Diego | |
| Ofatumumab & Ibrutinib + Allogeneic Bone Marrow Transplant or Consolidation in High Risk Chronic Lymphocytic Leukemia | NCT02388048 | Leukemia, Lymph... | Ibrutinib + ofa... | 18 Years - 65 Years | Gruppo Italiano Malattie EMatologiche dell'Adulto | |
| EZN-3042 Administered With Re-induction Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL) | NCT01186328 | Lymphoblastic L... Lymphoblastic L... Leukemia, Lymph... Leukemia, Lymph... | EZN-3042 Cytarabine Doxorubicin Prednisone Vincristine PEG-asparaginas... Methotrexate Hydrocortisone | 1 Year - 21 Years | Therapeutic Advances in Childhood Leukemia Consortium | |
| Comparing Two Diets in Patients Undergoing HSCT or Remission Induction Chemo for Acute Leukemia and MDS (UF-BMT-LDND-101) | NCT03016130 | Leukemia Myelodysplastic... | Diet | 18 Years - | University of Florida | |
| Study of TBI-1501 for Relapsed or Refractory Acute Lymphoblastic Leukemia | NCT03155191 | Lymphoblastic L... | TBI-1501 | 16 Years - | Takara Bio Inc. | |
| AC220 for Children With Relapsed/Refractory ALL or AML | NCT01411267 | Lymphoblastic L... Myelogenous Leu... | AC220 Cytarabine Etoposide Methotrexate | 1 Month - 21 Years | Therapeutic Advances in Childhood Leukemia Consortium | |
| A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML | NCT01861002 | Lymphoblastic L... Myelogenous Leu... | Azacytidine Fludarabine Cytarabine Intrathecal (IT... Intrathecal Met... | 1 Year - 21 Years | Therapeutic Advances in Childhood Leukemia Consortium | |
| Study Protocol: Study on Incidence and Risk Factors of Mold Infections in Children During Leukemia Treatment | NCT05774990 | Leukemia, Myelo... Acute Lymphobla... | - 17 Years | University of Southern Denmark | ||
| Safety and Efficacy of an Adult Acute Lymphoblastic Leukemia Chemotherapy for Adult Lymphoblastic Lymphoma | NCT00195871 | Lymphoblastic L... | Prednisone, vin... hematopoietic s... | 18 Years - 59 Years | Centre Henri Becquerel | |
| Administration of Donor MultiTAA-Specific T Cells for ALL | NCT02475707 | Leukemia, Lymph... | MultiTAA-specif... | - | Baylor College of Medicine |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
